F-10POS: Oncolytics Biotech Deregisters Unsold Securities
Deregistration of Securities
Oncolytics Biotech Inc. has filed a post-effective amendment to deregister unsold securities from multiple previous F-10 registration statements.
Summary
- Oncolytics Biotech Inc. is filing a post-effective amendment to remove unsold securities from ten previous F-10 registration statements.
- These registration statements were originally filed between February 5, 2007, and July 25, 2024.
- The purpose of this filing is to withdraw the registration of securities that were not sold under these previous statements.
- The company certifies that it meets all requirements for filing on Form F-10.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine administrative action to deregister unsold securities and does not reflect current operational performance or future strategic direction.
Future Outlook
This filing does not contain forward-looking statements or guidance; it pertains to the deregistration of previously registered but unsold securities.
Industry Context
StockSavvy.ai notes that this filing is a procedural administrative action by Oncolytics Biotech Inc. to clean up its SEC filings by removing registration statements for securities that were never issued or sold. This is a common practice for companies that have had shelf registrations active for extended periods without utilizing them fully.
Stakeholder Impact
- Shareholders: No direct impact on current share count or ownership structure. This filing is administrative and does not involve new issuances or sales of securities.
Next Steps
- The post-effective amendment will become effective on April 16, 2026, at 4:30 p.m. Eastern time, at which point the unsold securities will be removed from registration.
Key Dates
| Date | Description |
|---|---|
| February 5, 2007 | Initial filing date for Registration Statement No. 333-140460. |
| February 8, 2007 | Initial filing date for Registration Statement No. 333-140529. |
| June 6, 2008 | Initial filing date for Registration Statement No. 333-151513. |
| June 2, 2010 | Initial filing date for Registration Statement No. 333-167250. |
| June 21, 2012 | Initial filing date for Registration Statement No. 333-182260. |
| July 25, 2014 | Initial filing date for Registration Statement No. 333-197633. |
| April 25, 2018 | Initial filing date for Registration Statement No. 333-224432. |
| June 8, 2020 | Initial filing date for Registration Statement No. 333-239025. |
| June 10, 2022 | Initial filing date for Registration Statement No. 333-265510. |
| July 25, 2024 | Initial filing date for Registration Statement No. 333-281009. |
| April 8, 2026 | Date of filing of the post-effective amendment. |
| April 16, 2026 | Proposed effective date for the post-effective amendment. |
Keywords
deregistration, unsold securities, registration statement, Form F-10, Oncolytics Biotech, SEC filing, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.